



## Sofra™ platform versatility shown via childbirth MRFF grant

### Highlights

- Hudson Institute receives \$1 million government grant
- Innovative project to treat widespread childbirth injuries
- Extension of Sofra™ oligonucleotides usage

**Sydney, 2 July 2026:** Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce that a Hudson Institute of Medical Research team has been awarded a \$1 million Medical Research Future Fund grant for a project involving the company's innovative [Sofra™](#) platform.

[Hudson Institute](#) is Noxopharm's strategic partner in the development of the Sofra technology, and the MRFF is an Australian Government research fund aiming to improve lives, build the economy and contribute to health system sustainability.

The grant is for a three-year project aiming to address the significant issue of birth injuries that lead to chronic and debilitating pelvic floor disorders (PFDs) in women.

According to industry research, approximately one in four women are affected by PFDs and there is currently no cure. The [global PFD treatment market](#) is currently worth US\$2.8 billion and is expected to grow to around US\$4.3 billion by 2032.

The Hudson Institute team will explore the use of Noxopharm's Sofra oligonucleotides to treat birth injuries by incorporating them into a topical cream designed to reduce the inflammation associated with development of PFDs and enable the conditions for tissue regeneration. This novel idea for a cream that would be easy to use, scale up and distribute has never been explored before in maternal pelvic health and obstetrics care.

The project mirrors Noxopharm's own development of [SOF-SKN™](#), which recently successfully completed a Phase I clinical trial. The Hudson Institute project demonstrates that using anti-inflammatory oligonucleotides in a skin cream could have applications across numerous skin-related diseases and conditions, each with potentially sizeable markets.

Noxopharm CEO Dr Olivier Laczka said: "Hudson Institute is at the forefront of inflammation-related research in Australia, and this is yet another example of their innovative approach to ongoing public health challenges. It also shows the versatility inherent in the Sofra platform, and how our technology can be used in a wide variety of circumstances to tackle inflammation."

**-ENDS-**



### **About the Sofra technology platform**

Developed from a [breakthrough discovery](#) in innate immunology, the Sofra technology platform represents a revolutionary approach to drug design by translating a new understanding of innate biology into targeted therapeutics that enable precision control of disease-relevant signalling.

Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body's defence system.

This novel approach enables selective and modular tuning of immune sensors, reducing or stimulating their associated biological responses to mitigate a broad range of diseases and enhance RNA-based therapies and emerging therapeutic technologies.

[Sofra](#) is focused on inflammatory and autoimmune diseases such as rheumatoid arthritis, lupus and diabetes, as well as immuno-oncology for cancer treatment. The global autoimmune disease therapeutics market was worth US\$163.2 billion in 2024 and is expected to reach US\$219.6 billion by 2035, while the worldwide immuno-oncology market was US\$43 billion in 2023 and is projected to hit US\$284 billion by 2033.

Further information and animations: [SOF-SKN](#) / [SOF-VAC](#)

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: [noxopharm.com](https://noxopharm.com)

### **About Hudson Institute of Medical Research**

A global bioscience medical research leader, Hudson Institute's sole focus is on powering breakthrough scientific discoveries into improved health care that will transform lives. We strive to improve human health through ground-breaking, collaborative medical research discoveries and their translation to real world impact. Hudson Institute scientists research five areas of medical need:

- Inflammation
- Reproductive health and pregnancy
- Infant and child health
- Cancer
- Hormones and health

To learn more, please visit: [www.hudson.org.au](https://www.hudson.org.au)



**Investor, Corporate & Media enquiries:**

Julian Elliott

M: +61 425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

**Company Secretary:**

Shawn van Boheemen

T: +61 414 903 376

E: [shawn.vanboheemen@noxopharm.com](mailto:shawn.vanboheemen@noxopharm.com)

**Hudson Institute Media enquiries:**

Rob Clancy

Communications & Media Manager

M: + 61 408 579 313

E: [rob.clancy@hudson.org.au](mailto:rob.clancy@hudson.org.au)

*Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.*

---

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.